Nature Communications (Mar 2022)

Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

  • Guanlan Xu,
  • Tiffany D. Grimes,
  • Truman B. Grayson,
  • Junqin Chen,
  • Lance A. Thielen,
  • Hubert M. Tse,
  • Peng Li,
  • Matt Kanke,
  • Tai-Tu Lin,
  • Athena A. Schepmoes,
  • Adam C. Swensen,
  • Vladislav A. Petyuk,
  • Fernando Ovalle,
  • Praveen Sethupathy,
  • Wei-Jun Qian,
  • Anath Shalev

DOI
https://doi.org/10.1038/s41467-022-28826-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Oral verapamil lowers inflammatory markers and daily insulin needs in subjects with type 1 diabetes and helps preserve pancreatic beta cell function for at least two years. In this context, serum chromogranin A provides a promising therapy marker.